The phenomenon of early endotoxin tolerance, which is induced by sublethal injection of lipopolysaccharide (LPS), results in a protracted period of hyporesponsiveness that is most profound at 3 to 4 days after injection and is marked by reduced cytokine production after a challenge injection of LPS. Early endotoxin tolerance is also induced by the nontoxic LPS derivative monophosphoryl lipid A (MPL), although much more of the monophosphoryl derivative is required to produce a state of tolerance equivalent to that evoked by LPS. In this study, equivalent tolerance-inducing doses of LPS and MPL were tested, and the levels of cytokines induced by LPS and MPL were compared. Although induced levels of colony-stimulating factor were comparable following doses of LPS and MPL that elicited an equivalent state of early endotoxin tolerance, levels of tumor necrosis factor, interleukin-6, and interferon were significantly lower in MPL-injected animals. These results suggest that the lowered toxicity of MPL may be related to its elicitation of significantly lower levels of potentially toxic intermediaries such as tumor necrosis factor, interferon, and interleukin-6.
Lipopolysaccharide (LPS) is a complex structure derived from the outer membrane of gram-negative bacteria. The varied toxic and beneficial activities induced by LPS in vivo and in vitro are mediated in large part by intercellular chemical messengers called cytokines. Specifically, the cytokines elaborated by macrophages, e.g., monokines, are produced in response to LPS and peak in activity at predictable times after LPS stimulation (42) . For example, within 2 h after injection of LPS, macrophage-secreted tumor necrosis factor (TNF; cachectin) (8, 9) , interleukin-1 (IL-1) (2, 20, 24) , and alpha-beta interferon (IFN-aI0) have peaked or are at peak concentrations in the serum. At 4 to 6 h after injection of LPS, colony-stimulating factor (CSF), IL-6, and glucocorticoid-antagonizing factor have been shown to rise to maximum levels (17, 18, 26, 28) . Collectively, these cytokines have been referred to as the early acute-phase reactants. These cytokines act upon a variety of target cells, which in turn effect both the deleterious symptoms of endotoxin shock and the more beneficial attributes associated with the response (i.e., increased resistance to infection, protection from lethal radiation, and excellent adjuvanticity [42] ).
In the Enterobacteriaceae, the biologically active fraction of the LPS molecule, lipid A, consists of an acylated D-glucosamine disaccharide which carries two phosphoryl groups, one at position four of the non-reducing-terminal glucosamine and one at position one of the reducing-terminal glucosamine (10) . The extent of acylation of the lipid A of a particular species of bacterium is intrinsically heterogeneous and nonstoichiometric, so that several structures may be represented even within a single preparation (10) . However, the predominance of one particular structure within the mixture is consistent for a given species of bacterium (32) . Monophosphoryl lipid A (MPL), a derivative of lipid A, is dephosphorylated at position one of the reducing-terminal glucosamine moiety (31) and has been shown to be signifi-* Corresponding author.
cantly less toxic than either lipid A or intact LPS (31) (32) (33) . It has also been shown to stimulate monokine production (21) and to facilitate tumor regression in vivo (31) .
The term endotoxin tolerance was first used to describe a period following administration of LPS during which animals failed to respond to subsequent injections of LPS (15) . Early endotoxin tolerance is observed after a single injection of LPS and peaks 3 to 4 days after the initial injection (45) . Animals gradually regain normal responsiveness approximately 8 days after the initial LPS injection. LPS is cleared from the serum during the period of hyporesponsiveness, and tolerance cannot be transferred to fully responsive animals via anti-LPS antibodies in the serum of tolerant animals (4) (5) (6) 15) . Macrophages derived from tolerant animals were found to produce reduced levels of endogenous pyrogen (12) and prostaglandins of the E series (11, 14, 20, 34) when stimulated with LPS in vitro.
Early endotoxin tolerance is inducible with serologically unrelated types of LPS as well as with the nontoxic lipid A derivative MPL (21) (22) (23) . Combined treatment of mice with recombinant preparations of IL-1 and TNF leads to a state of hyporesponsiveness akin to early endotoxin tolerance, as evidenced by decreased production of CSF in response to a challenge injection of LPS 3 days after the administration of cytokines (43, 46) .
Since both LPS and MPL have been shown to induce early endotoxin tolerance, as measured by an equivalent reduction in CSF production or an increase in LD50 (dose required to kill 50% of test animals; 50% lethal dose) following LPS challenge, there appeared to be an inconsistency: if both toxicity and tolerance are cytokine mediated and both MPL and LPS induce early endotoxin tolerance, why is MPL less toxic? In this study, equivalent tolerance-inducing doses of MPL and LPS were established and the levels of cytokines induced by these doses of LPS and MPL were compared. The results suggest that differential patterns of cytokine induction by LPS and MPL may partially account for the biological differences observed.
MATERIALS AND METHODS
Mice. Female C57BL/6J mice, 5 to 6 weeks old, were obtained from Jackson Laboratories (Bar Harbor, Maine), and female C3H/HeN mice were obtained from the National Cancer Institute (Fredrick, Md.). Mice were used within 1 week of receipt. Mice were housed in a laminar flow hood and were fed standard lab chow and acid water ad libitum.
Reagents. The Escherichia coli K235 LPS used in this study was prepared by the phenol-water extraction method of McIntire et al. (25) and was shown by modified protein assay to contain <0.008% protein (19) . MPL from Salmonella typhimurium and Salmonella minnesota was obtained from RIBI Immunochem Research, Inc. (Hamilton, Mont.). Lot numbers 039-119, 038-104, 039-158, and 038-110 were used in this study.
Tolerance induction protocol. Induction of early endotoxin tolerance was carried out as described elsewhere (21) (22) (23) . Mice were divided into groups of three to eight mice per treatment and were injected intraperitoneally with 0.25 ml of pyrogen-free saline, 25 ,ug of LPS or the indicated concentration of MPL in 0.25 ml of saline on day 0. The concentrations of LPS and MPL used were established previously (21) and were confirmed for the multiple lots of MPL purchased for this study. A 200-,ug dose of MPL consistently led to tolerance equivalent to that induced by 25 ,g of LPS, as assessed by inhibition of LPS-induced CSF (21) . Three days later (day 3), one group of saline-inoculated mice was reinoculated with saline, and the other groups were challenged with 25 pLg of LPS in 0.25 ml (approximately 1/10 the LD50). Six hours after challenge injection, all mice in each group were bled from the retroorbital plexus. Pooled blood samples were allowed to clot and centrifuged, and the separated serum samples were frozen at -20°C until testing was performed.
Initial injection protocol. Mice were injected intraperitoneally with 0.25 ml of pyrogen-free saline as a control, 25 ,ug of LPS or 200 ,ug of MPL in 0.25 ml of saline at time zero. Individual groups of mice were bled at the indicated times postinjection. Serum was collected, and the pooled serum samples were frozen immediately at -20°C until testing was performed. Results for C57BL/6J and C3H/HeN mice have been pooled because they were indistinguishable from each other. Results for S. minnesota and S. typhimurium MPL were also pooled, since the two varieties of MPL tested were indistinguishable for all parameters tested.
Measurement of CSF activity in serum. Serum was tested for CSF activity in a bone marrow colony assay in semisolid agar as described previously (21-23, 41, 46) . Briefly, serum samples were tested for CSF activity as follows. Bone marrow cells obtained from tibias and femurs of C3H/HeJ (LPS hyporesponsive) mice were pooled and processed by gradient density centrifugation in lymphocyte separation medium (Litton Bionetics, Kensington, Md.). Cells from the gradient interface were collected and diluted to 105 cells per ml in a mixture of tissue culture medium and molten agar. One milliliter of the cell suspension was added to each well of a six-well tissue culture plate (Costar, Cambridge, Mass.) which contained 0.2-ml serial dilutions of test serum per well. The contents of the wells were mixed by swirling and allowed to solidify. Cultures were incubated at 37°C and 6% CO2 for 6 to 7 days. Colonies containing 25 or more cells were enumerated with a dissecting microscope. CSF activity, expressed as units per milliliter, was calculated by multiplying the number of colonies per well by the reciprocal of the final dilution of the sample. Only colony numbers on the linear portion of the dilution curve were used to calculate CSF concentration (46) . IFN assay. IFN activity was determined for pooled serum samples by a modification (21, 41) of the method of Rubinstein et al. (37) . Serial twofold dilutions of serum samples were prepared in 50-pI volumes in flat-bottomed 96-well culture dishes (Falcon Plastics, Oxnard, Calif.). To each well was added 50 ,ul of L929 fibroblasts (105 cells per well). After a 24-h incubation at 37°C and 6% C02, the supernatants were aspirated, and the cells were infected with 100 ,u of vesicular stomatitis virus (Indiana strain) per well in medium containing 10% fetal calf serum, at a multiplicity of infection of 0.1. At 18 to 24 h postinfection, the cells were washed three times with cold Earle balanced salt solution and fixed for 10 min with 5% formaldehyde. The cells were stained for 5 min with 0.5% crystal violet in 20% ethanol, and the plates were subsequently washed with tap water and allowed to dry. and 40,960 U/ml (i.e., 2,048 U/50 pA), respectively (19) .
IL-6 assay. IL-6 activity was measured in a hybridoma cell proliferation assay, described in detail elsewhere (1, 40) .
Briefly, B-9 hybridoma cells were treated with 10-fold serial dilutions of test sera, and proliferation was allowed to occur for 72 h. Proliferation was scored by incorporation of tritiated thymidine for 18 h. IL-6 activity is also expressed as units per milliliter. An IL-6 unit is defined as the reciprocal of the final dilution of sample which induced half-maximal proliferation.
glucose standard solution per dl. These standard solutions were treated the same as the test samples. Twenty-five microliters of test samples and standard solutions was diluted 1:5 with 100 ,u of deionized water; then, 20 RI of each diluted sample was placed into each of six replicate wells of a 96-well plate (Falcon Plastics, Oxnard, Calif.). To each well, 200 RI of glucose oxidase enzyme-color reagent solution was added. A 20-pI amount of deionized water in each of six wells served as a blank. Plates were incubated for 30 min at 37°C before the A450 was read. The mean of the six wells for each sample was used to extrapolate the glucose concentration of the sample after linear regression analysis of the standard curve.
RESULTS
Induction of tolerance by LPS and MPL. In a previous study, it was shown that MPL could induce early endotoxin tolerance in outbred mice, although a significantly higher dose of MPL than of intact LPS was required to achieve the same degree of tolerance (21) . Figure 1 shows the results of series of experiments in which LPS and MPL were compared for their ability to induce early endotoxin tolerance inbred mice, as assessed by production of CSF after LPS challenge. With C57BL/6J and C3H/HeN mice, a significantly higher dose of MPL was required to induce the same degree of tolerance observed when 25 ,ug of E. coli LPS was administered as the tolerance-inducing agent. A 25-,ug dose of LPS administered on day 0 reduced the level of CSF produced in response to a challenge injection of 25 ,ug of LPS on day 3 to 26% of that of the saline-pretreated control group. A 200-,ug dose of MPL was found to reduce CSF upon LPS challenge equivalently, to 31% of control levels. Doses of 50 and 100 ,ug of MPL induced only partial tolerance, as evidenced by suboptimal reduction of CSF activity. Tolerance induction data for LPS and MPL in C3H/HeN and C57BL/6J mice were not statistically different, nor were results with MPL derived from S. typhimurium or S. minnesota (data not shown). Thus, using the induction of CSF as an indicator of LPS responsiveness, we established that 200 Rxg per mouse was a tolerance-inducing dose for MPL, since it reduced CSF to levels comparable to those in mice made tolerant by 25 ,ug of LPS. For all other experiments, the responses of animals treated with 200 ,g of MPL or 25 ,ug of LPS were compared at the indicated times after challenge injection with 25 ,ug of LPS.
Another measure of LPS-induced toxicity is the induction of hypoglycemia (7). We next compared the capacity of LPS and MPL to mitigate LPS-induced hypoglycemia upon challenge (Fig. 2) . Challenge with LPS on day 3 induced severe hypoglycemia in saline-injected controls, reducing the serum glucose concentration by 45% 6 h after injection. In mice treated with either 25 ,ug of LPS or 200 ,ug of MPL, the fall of serum glucose in response to LPS challenge on day 3 was only 24% (P < 0.05). As was observed for CSF ( Fig. 1) , lower doses of MPL (100 ,ug) were found not to protect mice from the LPS challenge-induced hypoglycemia (Fig. 2) .
LPS-induced IFN antiviral activity was also compared in mice treated with MPL and LPS. IFN levels peaked in saline-treated controls at 2 h following LPS challenge and declined thereafter. Although both LPS and MPL induced tolerance for subsequent LPS-induced IFN, MPL was not as effective as LPS in reducing the amount of postchallenge antiviral activity detected. IFN levels were significantly higher in MPL-treated mice than in those treated with LPS at 2 h but not at 6 h postchallenge (Fig. 3) .
When tolerance induction by MPL and LPS was compared with respect to postchallenge levels of circulating TNF, MPL was found to induce tolerance with respect to TNF production, but as was observed for IFN, it was not as efficient as LPS (Fig. 4) . TNF production peaked 1 h postchallenge injection, and in both the LPS-and MPLtreated groups, production of TNF was reduced significantly below the levels produced in the group treated with saline. This reduction in TNF activity was even more striking at 2 h following LPS challenge.
In two separate experiments, IL-6 levels were also compared in LPS-and MPL-treated mice following challenge injection. Both MPL and LPS inhibited production of IL-6 induced by LPS challenge ( Table 1) .
Induction of cytokines upon initial injection of LPS and MPL. Since both LPS and MPL induced early endotoxin tolerance, experiments were performed to compare directly the levels of cytokines induced by the initial injection of a tolerance-inducing dose of each. When CSF levels were compared, there were no significant differences between the levels induced by equivalent tolerance-inducing doses of MPL and LPS (Fig. 5) . Although a tendency was noted for the MPL-induced CSF level to decrease after 4 h, the difference between LPS-and MPLinduced CSF levels at 6 h was not statistically significant by Student's t test. When IFN ( Table 2 ) and TNF (Table 3) levels were compared after initial injection, MPL elicited significantly less of each cytokine than did LPS. The peak of IFN antiviral activity induced by LPS at 2 h postinjection was significantly greater than that found in MPL-injected mice. Maximal IFN activity induced by MPL was less than that elicited by LPS by a factor of approximately 10. The peak of TNF activity, at 1 h after injection of MPL and LPS, was also approximately 10-fold less in MPL-injected mice.
IL-6 production peaked between 2 and 4 h after LPS or MPL injection. As was observed for TNF and IFN, peak IL-6 activity induced by LPS was more than 10-fold greater than that induced by injection of MPL in each of three experiments (Fig. 6 ). DISCUSSION Macrophage-derived monokines are believed to contribute significantly to many physiological alterations attributed to endotoxin administration (42) . It is now recognized that many of the LPS-induced cytokines serve multiple functions, and when administered to animals, they can mimic the biologic responses induced by LPS (3, 43) . It is also well established that structurally unrelated cytokines often exhibit overlapping activities. For example, fever is a classic symptom associated with LPS administration. Administration of any of three distinct LPS-induced cytokines, IL-1, TNF, and IFN, leads to prostaglandin-mediated fever like that seen in response to LPS. In addition, a high concentration of recombinant TNF causes two temperature spikes: the first is TNF induced, and the second is caused by TNFstimulated IL-1 production (14) . Collectively, these factors are referred to as endogenous pyrogens. Thus, multiple factors induced by LPS can potentially contribute to the elicitation of a given biological response.
Hypoglycemia is another manifestation of endotoxemia. There are several potential ways for this to occur. First, LPS stimulates glucose consumption by monocytic phagocytes and proliferating B-and T-cell populations (38) . Second, LPS induces a macrophage-derived soluble factor(s) referred to as glucocorticoid-antagonizing factor (27, 28) . Glucocor- ticoid-antagonizing factor inhibits glucocorticoid-induced phosphoenolpyruvate carboxykinase, a liver enzyme which controls the rate-limiting step in gluconeogenesis (35, 36) . Both recombinant IL-1 and recombinant TNF have been shown to induce hypoglycemia in vivo (3, 17) . Another phenomenon induced by LPS and mimicked by cytokine administration is a transient state of hyporesponsiveness which is called early endotoxin tolerance (15) . The phenomenon is not transferrable with serum (16) , but reticuloendothelial blockade inhibits tolerance induction (4) . Macrophages from LPS-treated mice have been shown to produce reduced levels of endogenous pyrogen and prostaglandin E2 when stimulated in vitro by LPS (11, 12, 14, 33) . Thus, the failure of tolerant macrophages to produce those soluble factors responsible for endotoxicity was proposed to be the cellular basis for early endotoxin tolerance.
This notion was confirmed and extended in vivo. Williams et al. (46) inducible CSF levels. Madonna and Vogel confirmed these results and showed that alterations in LPS-induced CSF and LD50 correlated with changes in bone marrow cell size and changes in numbers of macrophage progenitors (22) . Subsequent studies showed that both toxicity and a state of LPS hyporesponsiveness could be induced by the highly dosedependent synergistic activity of recombinant IL-lot and recombinant TNF-a and that the doses which resulted in tolerance also led to the previously described hematopoietic changes (43) .
In 1984, Ribi and his colleagues characterized a nontoxic derivative of LPS called MPL (31) . Madonna et al. showed that MPL could also induce early endotoxin tolerance (21) , as evidenced by an inhibition of LPS-induced CSF production, as well as by a significant increase in LD50. The purposes of this study were (i) to extend these findings to include study of hypoglycemia and the effect of tolerance on the production of other cytokines and (ii) to examine the relative cytokine-inducing capacities of equivalent tolerance-inducing doses of LPS and MPL. We found that the tolerance-inducing effect of 25 jig of LPS could be reproduced by administration of 200 ,ug of MPL, as assessed by LPS-induced CSF production ( Fig. 1) (21) , hypoglycemia (Fig. 2) , and IL-6 production (Table 1) . However, the same dose of MPL was somewhat less "tolerogenic" than LPS with regard to IFN and TNF production ( Fig. 3 and 4) . Nonetheless, administration of MPL resulted in early endotoxin tolerance, as evidenced by a significant decrease in both TNF and IFN levels evoked after LPS challenge injection ( Fig. 3 and 4 ). These findings demonstrate that early endotoxin tolerance can be induced by both LPS and MPL for a wide spectrum of LPS-induced effects.
Since cytokines have been shown to induce early endotoxin tolerance as well as LPS-like toxicity, analysis of the cytokines induced after administration of equivalent doses of LPS and MPL might provide insights into which contribute to toxic versus tolerance-inducing manifestations. We observed that 25 jig of LPS and 200 ,ug of MPL induced comparable levels of CSF following initial injection, but the levels of IFN, TNF, and IL-6 induced were approximately 10-fold lower in the MPL-injected mice (Tables 2 and 3 ; Fig.  6 ). These findings might be interpreted to mean that induction of early endotoxin tolerance is caused solely by the action of CSF. Alternatively, it is possible that tolerance is induced by a substance not measured in our experiments or is the result of some nontoxic combination of cytokines that are elicited by MPL as well as LPS. This latter possibility is consistent with the synergistic toxicity observed between recombinant IL-lot and TNF-a in vivo, whereas lower-dose combinations of these two cytokines results in a tolerant state. Thus, the diminished toxicity of MPL compared with LPS may be due to its induction of significantly lower levels of toxic intermediaries such as TNF, IFN, and IL-6 upon initial injection, and yet enough may be produced to permit the low-dose synergy required for tolerance induction. conformation of the lipid A moiety and reduces its toxicity (32) . Perhaps these conformational differences cause MPL to bind with a lowered affinity to a putative LPS signalling receptor, or the conformation of MPL facilitates its interaction with alternative lipid A binding proteins. Induction of lower levels of toxicity-producing cytokines may be related to differences in transmembrane signalling during the interaction of MPL and LPS with cell surface LPS-binding proteins. This is supported by the fact that an equivalent tolerance-inducing dose of MPL induces significantly lower levels of toxic-symptom-producing cytokines, such as TNF, upon initial injection than does LPS. Study of the interac- tions of LPS and MPL with LPS-binding proteins may provide further insights into the mechanisms of endotoxin shock and early endotoxin tolerance.
